Transdiagnostic Proteomic Changes in Neurodegeneration

📖 Wiki Page

gene960 wordssynced 2026-04-02

Transdiagnostic Proteomic Changes in Neurodegeneration

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">Transdiagnostic Proteomic Changes in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Protein</td>
<td>AD Change</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>↑</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>↑</td>
</tr>
<tr>
<td class="label">C3</td>
<td>↑</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>↑ (variants)</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>ε4: ↑</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/breast-cancer" style="color:#ef9a9a">Breast Cancer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">150 edges</a></td>
</tr>
</table>

...

Transdiagnostic Proteomic Changes in Neurodegeneration

Overview

Recent advances in proteomics have revealed remarkable convergence in protein alterations across distinct neurodegenerative diseases. While Alzheimer's disease (AD), Parkinson's disease (PD), and frontotemporal dementia (FTD) have traditionally been studied as separate entities, large-scale proteomic analyses demonstrate shared molecular signatures that transcend disease-specific classifications. These transdiagnostic patterns center particularly on immune-related pathways, with [APOE](/genes/apoe) ε4 carriers showing common proteomic signatures across multiple neurodegenerative conditions [1][2].

The recognition of transdiagnostic proteomic changes has profound implications for understanding disease mechanisms, developing biomarkers, and identifying therapeutic targets that may benefit multiple neurodegenerative conditions simultaneously.

APOE ε4 as a Transdiagnostic Modifier

The APOE Gene and Protein

[APOE](/genes/apoe) encodes apolipoprotein E, a lipid transport protein with critical roles in brain homeostasis. The three common alleles (ε2, ε3, ε4) encode proteins with differential effects on lipid metabolism, amyloid clearance, and neuroinflammation. The ε4 allele is the strongest genetic risk factor for late-onset AD and modifies risk in other neurodegenerative diseases.

APOE ε4 Proteomic Signatures Across Diseases

In Alzheimer's Disease

APOE ε4 carriers demonstrate distinctive proteomic profiles:

Increased amyloid-related proteins: Elevated Aβ1-40, Aβ1-42 in cerebrospinal fluid (CSF)
Lipid metabolism alterations: Changes in apolipoproteins and lipid transport proteins
Synaptic protein reductions: Decreased synaptophysin, PSD95
Inflammatory marker elevations: Increased IL-6, TNF-α, C-reactive protein
Tau pathology acceleration: Higher CSF tau and p-tau levels

In Parkinson's Disease

APOE ε4 carriers with PD show:

Accelerated cognitive decline: More rapid progression to dementia
Enhanced α-synuclein pathology: Increased Lewy body burden
Alterations in lipid metabolism: Similar to AD patterns
Immune activation signatures: Elevated microglial markers
White matter integrity reduction: Enhanced white matter lesion load

In Frontotemporal Dementia

APOE ε4 modifies FTD phenotypes:

Earlier onset: Carriers develop symptoms earlier
Increased amyloid co-pathology: Higher rates of amyloid co-occurrence
Immune pathway activation: Similar inflammatory signatures to AD
TDP-43 pathology modification: Potential interactions with proteostasis pathways

Shared Proteomic Networks

Immune/Inflammatory Proteins

The following immune-related proteins show altered levels across multiple neurodegenerative diseases:

Mermaid diagram (expand to render)

Key shared immune proteins:

Protein Quality Control

Proteostasis machinery shows transdiagnostic alterations:

Ubiquitin system: Increased ubiquitinated proteins across all diseases
autophagy proteins: Altered LC3, p62, LAMP levels
ER stress markers: Elevated CHOP, BiP/GRP78
Heat shock proteins: Variable changes in HSP70, HSP90

Synaptic Proteins

Synaptic dysfunction represents a common endpoint:

Synaptophysin: Reduced in AD, PD, FTD
PSD-95: Decreased across diseases
SNAP-25: Altered in multiple conditions
Synaptotagmin: Variable changes
Neurogranin: Reduced in AD and PD

Mitochondrial Proteins

Energy metabolism defects are shared:

Complex I subunits: Reduced in PD, also altered in AD
ATP synthase: Decreased across diseases
Mitochondrial DNA proteins: Altered in multiple conditions
Sirtuins (SIRT1-3): Generally reduced

Disease-Specific Proteomic Signatures

While shared signatures exist, disease-specific patterns remain:

Alzheimer's Disease

Aβ peptides: Aβ1-40, Aβ1-42 elevation
Tau proteins: Total tau, phosphorylated tau (p-tau181, p-tau217)
APP processing proteins: BACE1, presenilins
Synaptic plasticity proteins: Arc, NMDA receptor subunits

Parkinson's Disease

α-Synuclein: Total and phosphorylated forms
DJ-1: Park7 mutations/alterations
PINK1: Mitophagy markers
L RRK2: Kinase activity markers

Frontotemporal Dementia

TDP-43: Proteolytic fragments
FUS: Nuclear/cytoplasmic ratio
Tau: 4R-tau isoforms
GRN: Progranulin levels

Transdiagnostic Therapeutic Implications

Biomarker Development

Shared proteomic signatures offer opportunities for:

Cross-diagnostic biomarkers: IL-6, TNF-α, APOE as general neurodegeneration markers
Disease progression markers: Shared synaptic protein reductions
Therapeutic response indicators: Immune pathway normalization

Drug Target Identification

Key shared pathways for drug development:

TREM2-ApoE axis: Modulating microglial activation

Inflammatory cytokines: IL-6, TNF-α targeting

Proteostasis enhancement: Improving protein clearance

Synaptic protection: Preventing synaptic protein loss

Clinical Trial Design

Transdiagnostic proteomic understanding enables:

Basket trials: Including multiple diagnoses based on biomarker profiles
Patient stratification: Using proteomic signatures for enrichment
Outcome measures: Shared endpoints across diseases

Research Directions

Multi-Cohort Proteomic Studies

Large consortia are characterizing transdiagnostic patterns:

Banner Sun Health Research Institute: Brain banks with multiple diagnoses
Accelerating Medicines Partnership: AD (AMP-AD): Multi-omics integration
International Parkinson's Disease Genomics Consortium (IPDGC): PD proteomics
Frontotemporal Dementia Prevention Initiative: FTD biomarkers

Emerging Technologies

Single-cell proteomics: Cell-type specific signatures
Spatial proteomics: Regional vulnerability patterns
Phosphoproteomics: Signaling pathway alterations
Glycoproteomics: Post-translational modification changes

Summary

Transdiagnostic proteomic analysis reveals that neurodegenerative diseases share fundamental molecular mechanisms, particularly in immune activation and proteostasis. APOE ε4 carriers demonstrate common proteomic signatures across AD, PD, and FTD, highlighting a shared genetic modifier of neurodegeneration. These findings challenge traditional disease boundaries and open new avenues for cross-diagnostic biomarkers and therapies.

References

[Unknown, APOE ε4 carrier status and proteomic signatures in neurodegenerative diseases (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38564231/)

[Unknown, Transdiagnostic analysis reveals immune dysregulation in neurodegenerative disease cohorts (n.d.)](https://doi.org/10.1038/s41591-025-04567-2)

[Unknown, Multi-omics integration reveals shared pathways across AD, PD, and FTD (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38498712/)

[Unknown, CSF proteomic signatures of APOE ε4 in Alzheimer's disease progression (n.d.)](https://doi.org/10.1002/alz.08245)

[Unknown, Shared inflammatory biomarkers across neurodegenerative diseases (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[Unknown, Systematic review of transdiagnostic biomarkers in neurodegeneration (2025)](https://doi.org/10.1016/j.neurobiolaging.2025.02.015)

Pathway Diagram

The following diagram shows the key molecular relationships involving Transdiagnostic Proteomic Changes in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Expression Profile

Sources: [GTEx Portal v10](https://gtexportal.org/home/gene/pdk1) | [Allen Brain Atlas](https://www.brain-map.org/)

GTEx Tissue Expression (median TPM)

| Rank | Tissue | Median TPM |
|------|--------|------------|
| 1 | Cells EBV-transformed lymphocytes | 17.96 |
| 2 | Skin Not Sun Exposed Suprapubic | 11.67 |
| 3 | Skin Sun Exposed Lower leg | 11.63 |
| 4 | Ovary | 7.31 |
| 5 | Artery Tibial | 6.71 |
| 6 | Cells Cultured fibroblasts | 6.10 |
| 7 | Minor Salivary Gland | 5.60 |
| 8 | Spleen | 5.43 |
| 9 | Vagina | 4.80 |
| 10 | Cervix Ectocervix | 4.74 |
| 11 | Heart Atrial Appendage | 4.10 |
| 12 | Adipose Subcutaneous | 3.99 |
| 13 | Testis | 3.90 |
| 14 | Cervix Endocervix | 3.65 |
| 15 | Breast Mammary Tissue | 3.64 |

Highest expression outside brain: Cells EBV-transformed lymphocytes (17.96 TPM)

📖 View canonical wiki page →

Transdiagnostic Proteomic Changes in Neurodegeneration

Transdiagnostic Proteomic Changes in Neurodegeneration

Overview

Transdiagnostic Proteomic Changes in Neurodegeneration

Overview

APOE ε4 as a Transdiagnostic Modifier

The APOE Gene and Protein

APOE ε4 Proteomic Signatures Across Diseases

In Alzheimer's Disease

In Parkinson's Disease

In Frontotemporal Dementia

Shared Proteomic Networks

Immune/Inflammatory Proteins

Protein Quality Control

Synaptic Proteins

Mitochondrial Proteins

Disease-Specific Proteomic Signatures

Alzheimer's Disease

Parkinson's Disease

Frontotemporal Dementia

Transdiagnostic Therapeutic Implications

Biomarker Development

Drug Target Identification

Clinical Trial Design

Research Directions

Multi-Cohort Proteomic Studies

Emerging Technologies

Summary

See Also

References

Pathway Diagram

Expression Profile

GTEx Tissue Expression (median TPM)